Reduced incidence and severity of acute
radiation mucositis by WF10 (IMMUNOKINE) as adjunct to standard of
care in the management of head & neck cancer patients.
Penpattanagul S. J Med Assoc Thai
2007;90:1590-600.
A phase II study to evaluate WF10 in
patients with late hemorrhagic radiation cystitis and proctitis.
Veerasarn V, Boonnuch W,
Kakanaporn C.
Gynecol Oncol 2006;100:179-84.
Differential effects on innate versus
adaptive immune responses by WF10. Giese T,
McGrath MS,Stumm S, Schempp H, Elstner E,
Meuer SC. Cell Immunol
2004;229:149-58.
Reduced recurrence of late hemorrhagic radiation cystitis by WF10
therapy in cervical cancer patients: a multicenter, randomized,
two-arm, open-label trial. Veerasarn V,
Khorprasert C,
Lorvidhaya V,
Sangruchi S, Tantivatana T, Narkwong L, et al. Radiother Oncol 2004;73:179-85.
Immunosuppression in xenotransplantation with WF10. Kemp K, Dieperink H,
Hansen A, Johansen A,
Jensen J. et al. Pharmacol Toxicol
2002;90:346-8.
Development of WF10, a novel macrophage-regulating agent.
McGrath MS, Kahn JO and Herndier BG.
Curr Opin Investig Drugs
2002;3:365-73.
Chlorite-hemoprotein interaction as key role
for the pharmacological activity of the chlorite-based drug WF10.
Schempp H, Reim M,
Dornisch K, Elstner EF.
Arzneimittelforschung 2001;51:554-62.
High-dose stabilized chlorite matrix WF10
prolongs cardiac xenograft survival in the hamster-to-rat model
without inducing ultrastructural or biochemical signs of
cardiotoxicity. Hansen A, Kemp K, Kemp E, Bouchelouche K, Bouchelouche P, Dieperink H et al. Pharmacol Toxicol
2001;89:92-5.
WF10
in xenotransplantation-a potential new approach.
Kemp E, Dieperink H,
Johansen A,
Jensen J,
Kemp G. et al. Transplant Proc 2000;32:1018-9.
The efficacy of chemically-stabilized
chlorite-matrix (TCDO) in the management of late postradiation
cystitis. Srisupundit S, Kraiphibul P, Linasmita V,
Chingskol K,
Veerasarn V. J
Med Assoc Thai 1999;82:798-802.
Balanced macrophage activation hypothesis: a biological model for
development of drugs targeted at macrophage functional states.
McGrath MS and Kodeljab V.
Pathobiology 1999;67:277-81.
Effect of WF10 (TCDO) on antigen presentation.
McGrath MS, Benike C, Kuehne FW and Engleman E.
Transplantation Proc
1998;30:4200-4.
Randomized, double-blind, placebo-controlled
trial of the immune modulator WF10 in patients with advanced AIDS.
Raffanti SP, Schaffner W, Blackwell RB,
Ching OA,
Kuhne FW.
Infection 1998;26:202-7.
Long-term Survival of a Stage D Prostate Cancer.
Kuhne HH, Bressel M,
Heitz M, Kuppers F, Loch T, Stockle M.
Aktuel Urol 1998;29:261-3.
A double-blind, placebo-controlled,
randomized trial to evaluate the role of tetrachlorodecaoxide in the
management of chemotherapy-induced oral mucositis. Malik, Moid I, Haq S,
Sabih M.
J Pain Symptom Manage 1997;14:82-7.
Influence of tetrachlorodecaoxide (Ryoxon) on the development of
leukemia after total-body gamma-irradiation.
Kempf SR, Blaszkiewitz K, Port RE, Ivankovic S. Oncology
1994;51:510-4.
Anticarcinogenic effect of tetrachlorodecaoxide after total-body
gamma irradiation in rats.
Kempf SR, Port RE, Ivankovic S. Radiat Res 1994;139:226-31.
Comparative study on the effects of chlorite oxygen reaction product
TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClO2)
with equimolar chlorite content on bone marrow and peripheral blood
of BDIX rats. Kempf SR, Blaszkiewitz K, Reim M,
Ivankovic S. Drugs Exp Clin Res 1993;19:165-74.
Inactivation of HIV infectivity by the chlorite-oxygen reaction product
tetrachlorodecaoxygen. Ennen J,
Werner K, Kuhne FW, Kurth R. AIDS 1993;7:1205-12.
Stimulation of hematopoietic cell recovery by tetrachlorodecaoxide
in sublethally irradiated mice. Mason KA, Murphy S, Milas L.
Radiat Res 1993;136:229-35.
Antimicrobial effects of the
tetrachlorodecaoxygen-anion complex on oropharyngeal bacterial
flora: an in vitro study. Stoll P,
Huber H, Pelz K, Weingart D. Chemotherapy 1993;39:40-7.
The effects of epinephrine, ibuprofen, and
tetrachlorodecaoxide on cutaneous microcirculation in thermally
injured hamsters. Da Costa R, Aggarwal
SJ, Diller KR, Baxter CR.
J Burn Care Rehabil
1992;13:396-402.
Effects of tetrachlorodecaoxide (TCDO) in
chronic radiation lesions of the rat colon. Sassy T,
Breiter N, Trott KR.
Strahlenther Onkol 1991;167:191-6.
Anti-inflammatory properties of a novel wound healing and
immunomodulating agent, tetrachlorodecaoxygen complex (TCDO).
Tissot M,
Roch-Arveiller M, Mathieu J, Giroud JP, Stahl KW.
Agents Actions
1990;31:368-74.
The
Tetrachlorodecaoxygen Complex Reverses the Effect of Cortisone on
Wound Healing.
Hatz RA, Kelley SF, Ehrlich HP.
Plastic Reconstructive Surgery 1989;84:953-9.
Tetrachlorodecaoxygen anion complex treatment after localized X
irradiation of the rat colon. Breiter N,
Sassy T,
Trott KR. Br J Radiol
1989;62:381-3.
Regenerative effects of tetrachlorodecaoxide in BD IX rats after
total-body gamma irradiation. Ivankovic S, Kempf SR.
Radiat Res 1988;115:115-23.
Improvement of tumor spheroid oxygenation by
tetrachlorodecaoxide.
Mueller-Klieser W,
Vaupel P. Int J Radiat Oncol Biol Phys
1987;13:49-54.
Increased resistance towards two systemic
experimental infections by tetrachlorodecaoxygen anion complex.
Possible implications of cellular and humoral immunity.
Gillissen G,
Kuhne FW,
Breuer-Werle M, Melzer B,
Ostendorp H. Arzneimittelforschung.
1986;36:1778-82.
To see publications for Transdermal Drug Delivery, click here.
To see publications for Technology, click here.
|
